Page last updated: 2024-08-05 11:05:16
amidopiperidine
null
ChEBI ID: 48613
Members (2)
Member | Definition | Role |
---|---|---|
am 251 | A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor. | AM-251 |
sr141716 | A carbohydrazide obtained by formal condensation of the carboxy group of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. It is a potent and selective cannabinoid receptor 1 (CB1R) antagonist. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse agonist at CB1 receptors. The drug was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was later withdrawn from market due to CNS-related adverse effects including depression and suicidal ideation. | rimonabant |
Research
Studies (3,020)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 205 (6.79) | 18.2507 |
2000's | 1,504 (49.80) | 29.6817 |
2010's | 1,189 (39.37) | 24.3611 |
2020's | 122 (4.04) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 61 (1.92%) | 5.53% |
Reviews | 240 (7.55%) | 6.00% |
Case Studies | 10 (0.31%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 2,866 (90.21%) | 84.16% |